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Ionizing Radiation Exposure and the Development of
Soft-Tissue Sarcomas in Atomic-Bomb Survivors
Dino Samartzis, DSc, MSc, Nobuo Nishi, MD, PhD, John Cologne, PhD, Sachiyo Funamoto, BS, Mikiko Hayashi, BA,
Kazunori Kodama, MD, PhD, Edward F. Miles, MD, Akihiko Suyama, MD, PhD, Midori Soda, MD, and Fumiyoshi Kasagi, PhD
Investigation performed at the Radiation Effects Research Foundation, Hiroshima and Nagasaki, Japan
Background: Very high levels of ionizing radiation exposure have been associated with the development of soft-tissue
sarcoma. The effects of lower levels of ionizing radiation on sarcoma development are unknown. This study addressed the
role of low to moderately high levels of ionizing radiation exposure in the development of soft-tissue sarcoma.
Methods: Based on the Life Span Study cohort of Japanese atomic-bomb survivors, 80,180 individuals were prospec-
tively assessed for the development of primary soft-tissue sarcoma. Colon dose in gray (Gy), the excess relative risk, and
the excess absolute rate per Gy absorbed ionizing radiation dose were assessed. Subject demographic, age-specific, and
survival parameters were evaluated.
Results: One hundred and four soft-tissue sarcomaswere identified (mean colon dose = 0.18 Gy), associated with a 39%
five-year survival rate. Mean ages at the time of the bombings and sarcoma diagnosis were 26.8 and 63.6 years,
respectively. A linear dose-response model with an excess relative risk of 1.01 per Gy (95% confidence interval [CI]: 0.13
to 2.46; p = 0.019) and an excess absolute risk per Gy of 4.3 per 100,000 persons per year (95% CI: 1.1 to 8.9; p =
0.001) were noted in the development of soft-tissue sarcoma.
Conclusions: This is one of the largest and longest studies (fifty-six years from the time of exposure to the time of follow-
up) to assess ionizing radiation effects on the development of soft-tissue sarcoma. This is the first study to suggest that
lower levels of ionizing radiation may be associated with the development of soft-tissue sarcoma, with exposure of 1 Gy
doubling the risk of soft-tissue sarcoma development (linear dose-response). The five-year survival rate of patients with
soft-tissue sarcoma in this population was much lower than that reported elsewhere.
Level of Evidence: Prognostic Level I. See Instructions for Authors for a complete description of levels of evidence.
S
oft-tissue sarcomas are malignant connective tissue le-
sions of mesenchymal origin that can manifest at any
location throughout the body, are challenging to treat,
and generally have been associated with poor prognostic out-
comes1-3. Soft-tissue sarcomas represent approximately 0.6% of
all cancer cases4. Various etiological risk factors, such as envi-
ronmental exposures to various chemicals5,6, viruses7, exogenous
hormonal influences8, increased body-mass index9, genetic de-
terminants10,11, and high levels of ionizing radiation12-23, have been
associated with the development of soft-tissue sarcoma.
Radiation-induced soft-tissue sarcomas may occur as sec-
ondary cancers attributed to radiation therapy12,14,15,24 or Thoro-
trast (thorium dioxide) induction13, with radiation doses from 9
gray (Gy) or higher16-23 and variable latency periods25. In fact,
worse prognostic outcomes have been associated with radiation-
induced soft-tissue sarcomas26-28; however, the role of low to
moderately high levels of ionizing radiation exposure on the
development of soft-tissue sarcomas is unknown. Until recently,
it was a long-held belief that bone sarcomas were induced by very
high levels of ionizing radiation exposure (i.e., >10Gy). However,
due to a recent study by Samartzis et al.29, which was based on
atomic-bomb survivors, the authors concluded that much lower
levels of radiation exposure than previously believed may lead to
the development of bone sarcomas.
Disclosure: None of the authors received payments or services, either directly or indirectly (i.e., via his or her institution), from a third party in support of
any aspect of this work. One or more of the authors, or his or her institution, has had a financial relationship, in the thirty-six months prior to submission of
this work, with an entity in the biomedical arena that could be perceived to influence or have the potential to influence what is written in this work. No
author has had any other relationships, or has engaged in any other activities, that could be perceived to influence or have the potential to influence what
is written in this work. The complete Disclosures of Potential Conflicts of Interest submitted by authors are always provided with the online version of the
article.
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Due to the increase of ionizing radiation exposure in
medical and occupational settings as well as a potential risk that
may stem from nuclear facility catastrophes (e.g., Chernobyl,
Three Mile Island, and Fukushima Daiichi)30-35, as well as those
associated with radiation therapy in general and newer, more
conformal techniques that tend to increase the amount of
normal tissue exposed to low to moderate doses of ionizing
radiation, there is a need to understand if these sources of
exposure may lead to the development of soft-tissue sarcoma.
Therefore, a prospective, longitudinal study was performed to
assess the role of low to moderately high levels (i.e., 0 to ap-
proximately 3 Gy) of ionizing radiation exposure on the de-
velopment of soft-tissue sarcomas in the context of the Life
Span Study (LSS) cohort of Japanese atomic-bomb survivors of
Hiroshima and Nagasaki.
Materials and Methods
Study Design and Population
Aprospective, longitudinal study was performed of atomic-bomb survivors(time of exposure: August, 1945) from Hiroshima and Nagasaki, Japan,
who were part of the LSS cohort (N = 120,321) of the Radiation Effects Re-
search Foundation (RERF) to assess the development of soft-tissue sarcoma.
Characteristics of the LSS cohort have been previously reported
29,36-42
. The last
update of the LSS was in 2001. This was the case because gathering of data and
materials in a systematic and meticulous manner in the prefectures of Hir-
oshima and Nagasaki took several years to complete. Some information ne-
cessitated special arrangement with local medical institutions. Since the tumor
registries of Hiroshima and Nagasaki were established on January 1, 1957, and
January 1, 1958, respectively, any individuals who were deceased, diagnosed
with cancer, or lost to follow-up before January of 1958 were excluded from the
study (Fig. 1). Furthermore, individuals with unknown doses or residencies
outside the cities at the time of the bombings were also excluded from the study
(Fig. 1). Colon doses were used as a good approximation to dose for all soft
tissue, and were estimated in units of weighted Gy according to the Dosimetry
System of 2002 (DSO2), making allowance for biological effectiveness in that
neutrons were weighted 10 and gamma 1
43
. Since disease mechanisms may
entail systemic effects following whole-body radiation exposure, colon dose has
been used to approximate whole-body doses in the LSS cohort, which also
facilitates comparisons between disease
39
.
Identification and Clinical Assessment of Sarcomas
Utilizing the Hiroshima and Nagasaki Tumor Registries, primary and malignant
soft-tissue sarcomas were identified and further verified on the basis of autopsy
reports, death certificate records, and tissue registry information
44
. Diagnosis of
soft-tissue sarcoma development was based on initial physician consultation and
treatment regarding tumor-related symptoms or diagnosis irrespective of symp-
toms further verified pathologically. If the tumor was discovered during an au-
topsy, it was considered as being pathologically diagnosed. Tumors diagnosed
outside of the tumor registry catchment area were excluded. The site of origin and
histological characteristics of the tumorswere identified based on theWorldHealth
Organization’s International Classification of Diseases for Oncology (ICD-O), 1st
to 3rd editions. Age at the time of the bombings, age at sarcoma diagnosis (attained
Fig. 1
Flow diagram of study population exclusions and inclusions. ATB = at time
of bombings.
TABLE I Soft-Tissue Sarcoma Rates by Colon Dose in Units of Weighted Gray (Gy), with Relative Weight of 10 for Neutrons
Versus Gamma Radiation









<0.005* (0.0007) 956,946 39 (41.6) 4.4 [3.1 to 5.9]
0.005 to 0.1 (0.030) 760,551 36 (32.7) 5.1 [3.6 to 7.0]
0.1 to 0.2 (0.14) 152,461 9 (6.7) 6.2 [3.0 to 11]
0.2 to 0.5 (0.32) 159,426 6 (7.0) 4.0 [1.6 to 8.1]
0.5 to 1 (0.70) 84,383 9 (3.7) 11.4 [5.5 to 21]
1 to 2 (1.3) 42,829 4 (1.8) 10.4 [3.2 to 24]
21 (2.4) 14,136 1 (0.5) 8.6 [0.5 to 38]
*Subjects with radiation dose <0.005 served as control subjects being exposed to either no or very minimal amounts of radiation equivalent to
annual background radiation doses, which facilitated comparisons to subjects with exposure to higher doses.
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age), duration from exposure to sarcoma development, development of metasta-
ses, and five-year survival rate were assessed.
Statistical Analysis
Descriptive and frequency analysis was calculated of various subject and radiation
parameters as well as for site of origin and histological types of soft-tissue sarcomas.
Rates were computed based on Poisson regression modeling of grouped survival
data
45
. Person-years of observation were accumulated from January 1, 1958, to the
event of first tumor diagnosis, death, or December 31, 2001, whichever came first.
After implementing appropriate background functions in age and year of birth,
various dose-response associations were assessed to determine the best-fitting
model (i.e., linear, linear quadratic, quadratic, spline, and threshold) and to assess
radiation effects on two scales: the multiplicative excess relative risk (ERR: total
rate= [background rate] · [11 ERR]) and the additive excess absolute rate (EAR:
total rate = background rate1 EAR). The ERR, which is the standard model used
in radiation epidemiology, allows for analysis of the excess radiation-related inci-
dence separately from background incidence. Models were fitted with use of Ep-
icure statistical software (Seattle, Washington)
45
. Effect modification by sex, age at
exposure, or age at sarcoma diagnosis was assessed with likelihood ratio tests that
made use of log-linear effect-modifier models on each scale. Dose-response
models and the ERR-EAR scales were compared with use of the Akaike in-
formation criterion (AIC) (the deviance plus twice the number of param-
eters, including the joint point in the case of the spline model or the
threshold in the case of the threshold model)
46,47
. The best-fitting model was
selected on the basis of the lowest value of the AIC. Kaplan-Meier analysis
was performed to determine the five-year survival rate. Mann-Whitney U
tests were performed to assess two independent samples. All p values were
two-sided and significance was declared at p < 0.05, considering the 95%
confidence interval (CI) bounds for precision.
Ethics Approval
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Results
There were 80,180 individuals who met the inclusion criteria,with a total of 2,170,732 person-years (37% males, 63%
females) of observation (Table I). Of those individuals, 104 soft-
tissue sarcoma cases were identified, which consisted of thirty-six
males (34.6%) and sixty-eight females (65.4%). The overall
crude incidence associated with soft-tissue sarcomas was 4.8
per 100,000 person-years (4.4 in males, 5.0 in females). The
crude baseline (<0.005 Gy exposure) incidence (observed
cases/person-years) was 4.1 per 100,000 person-years, similar
to the age-and-birth-year-adjusted incidence of 4.4 per
100,000 person-years in that group (Table I). Twenty-seven
cases were confirmed on autopsy and two were confirmed by
death certificate. No difference in radiation dose was noted
between those cases confirmed on autopsy or death (mean:
0.24 Gy; ± standard deviation [SD]: 0.53 Gy; range: 0 to 2.35
Gy) compared with those diagnosed alternately (mean: 0.16
Gy; ± SD: 0.35 Gy; range: 0 to 1.82 Gy) (p = 0.279).
Among the soft-tissue sarcoma cases, the mean age at the
time of the bombings was 26.8 years (± SD: 15.9 years; range:
zero to seventy years) and the mean age at diagnosis was 63.6
years (± SD: 14.0 years; range: twenty-six to ninety-three
years). The time period from exposure to diagnosis (potential
latency period) of the sarcoma was 36.8 years (± SD: 12.5 years,
range: fourteen to fifty-six years). The mean colon dose was
0.18 Gy (± SD: 0.40 Gy, range: 0 to 2.35 Gy).
The majority of cases occurred in the uterus (n = 17,
16.3%) and stomach (n = 14, 13.5%) (Table II). According
to histology, the majority of sarcomas were leiomyosarcomas
(n = 37, 35.6%) and malignant fibrous histiocytomas (n = 11,
10.6%) (Table III). Due to varied site of origin and histology,
the authors could not discern with confidence the effects of
colon-dose radiation exposure and the development of specific
sarcoma types.
TABLE II Site of Origin of Soft-Tissue Sarcomas in Atomic-Bomb
Survivors




Extremities (n = 10)
Head/face/neck (n = 6)
Thorax (n = 2)
Pelvis (n = 4)
Abdomen (n = 1)
Trunk, NOS* (n = 5)
Uterus 17 (16.3)
Stomach 14 (13.5)
Cavities of the trunk (mediastinum,
peritoneum, and retroperitoneum)
9 (8.7)






Neural (cerebral, peripheral) 3 (2.9)
Breast 2 (1.9)






*NOS = not otherwise specified.
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Adjusting for age at diagnosis and year of birth, incidence
was higher among exposed persons than among persons with
<0.005 Gy exposure, evidencing a trend despite the small
numbers of cases and with persons exposed to >0.5 Gy showing
observed numbers of cases about double the number expected
if there were no radiation effect (Table I). ERR model com-
parisons of radiation effect on soft-tissue sarcoma development
revealed that a linear dose-response model fit better (AIC =
968.15) than linear-quadratic (AIC = 970.09), quadratic (AIC =
969.43), spline (AIC = 971.85), or threshold (AIC = 969.93)
models. The linear ERR, 1.01 per Gy (95% CI: 0.13 to 2.46, p =
0.019), was significant (Fig. 2). In addition, the risk of sarcoma
development significantly increased with increasing year of
birth (p = 0.037) and with increasing age at diagnosis (p <
0.001); however, sex was not a strong predictive factor (p >
0.5). With the EAR model, the estimated excess rate per Gy
was 4.32 per 100,000 persons per year (95% CI: 1.14 to 8.94,
p = 0.001). The ERR and EAR remained significant after ex-
cluding persons exposed to 2 Gy ormore (ERR 1.23, 95%CI: 0.18
to 2.94, p = 0.015; EAR 4.92, 95% CI: 1.06 to 10.40, p = 0.006).
The ERRmodel demonstrated significant radiation effect
modification by age of diagnosis (log-linear effect modifier
parameter 23.7, 95% CI: 26.4 to 20.8, p = 0.017, AIC =
962.40), but not the EAR model (p > 0.5; for unmodified
EAR, AIC = 961.49). Neither sex nor age at exposure sig-
nificantly modified the ERR marginally (p = 0.38 and p =
0.065, respectively) or after accounting for modification by
age of diagnosis (p > 0.5 and p = 0.43, respectively), nor did
either factor modify the attained-age-constant EAR (p > 0.5
and p = 0.21, respectively). The log-linear parameter for
log age in the unmodified EAR model was 3.4 (95% CI: 2.30
to 4.70), consistent with the attained age modifier of the
ERR (23.7).
Based on the last LSS assessment of soft-tissue sarcoma
cases, twenty-three individuals were alive (22.1%). Metas-
tases had occurred in forty-six individuals (44.2%) by the
time of the last follow-up. The mean survival period after
diagnosis was 7.1 years (± SD: 9.1 years; range: zero to forty-
four years). The five-year survival rate was 39%, which did
not statistically differ between sex, age at diagnosis, and
sarcoma site of origin or histology (p > 0.05). Regression
analysis did not note such factors to be significantly predic-
tive in this population. However, individuals in whom me-
tastases developed had a significantly shorter survival period
(mean: 3.0; ± SD: 4.0; range: zero to twenty-one years) than
did those without metastases (mean: 9.5; ± SD: 8.7; range:
zero to thirty-one years) at the time of the last assessment
(p < 0.001). The five-year survival rate for individuals in
whom metastases developed as compared with those with no
metastases was 17.4% and 53.4%, respectively (Fig. 3). The
effects of treatment type on survival rate could not be discerned
from this study.
TABLE III Histology of Soft-Tissue Sarcomas in Atomic-Bomb
Survivors
Histology No. of Cases (%)
Leiomyosarcoma 37 (35.6)
Malignant fibrous histiocytoma 11 (10.6)
Malignant mixed tumor 8 (7.7)
Malignant peripheral nerve sheath tumor 7 (6.7)
Hemangiosarcoma 6 (5.8)
Fibrosarcoma 6 (5.8)
Endometrial stromal 4 (3.8)
Soft-tissue sarcoma, NOS* 4 (3.8)
Liposarcoma 3 (2.9)
Carcinosarcoma 2 (1.9)
Malignant cystosarcoma phyllodes 2 (1.9)
Dermatofibrosarcoma 2 (1.9)
Mu¨llerian mixed tumor 2 (1.9)
Myxofibrosarcoma 1 (1.0)
Malignant granular-cell tumor 1 (1.0)
Malignant hemangioendothelioma 1 (1.0)
Malignant hemangiopericytoma 1 (1.0)
Malignant meningioma 1 (1.0)
Myxoid liposarcoma 1 (1.0)
Pleomorphic liposarcoma 1 (1.0)
Rhabdomyosarcoma 1 (1.0)
Small cell sarcoma 1 (1.0)
Synovial sarcoma 1 (1.0)
Total 104 (100%)
*NOS = not otherwise specified.
Fig. 2
Illustration of various excess relative risk (ERR) dose-response models for
colon dose in units of weighted gray (Gy), with a relative weight of 10 for
neutrons comparedwith gamma radiation. Baselinemodels were adjusted
for age at the time of sarcoma diagnosis and year of birth.
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Discussion
Exposure to ionizing radiation can lead to tissue damageand genetic mutation, resulting in numerous cancerous
or noncancerous diseases48,49. Ionizing radiation exposure has
been of paramount public-health concern, further brought to
light due to the recent breakdown of the Fukushima Daiichi
nuclear power plant in Japan in March of 2011. Although
radiation therapy is often utilized to treat cancerous lesions,
studies have shown that the use of ionizing radiation mo-
dalities (e.g., radiographs, computed tomography scans, fluo-
roscopy) for diagnostic and as surgical adjuncts continues to
rise and that these modalities on many occasions have been
utilized quite liberally, increasing radiation exposure to the
patient and at times to the health-care practitioner30-32,34,50. In
fact, the use of ionizing radiation in the medical setting in the
United States has increased fourfold from the early 1980s to
200651.
The atomic-bomb survivors of Hiroshima and Naga-
saki, Japan, are the world’s largest and most unique source of
information to assess the effects of low to moderately high
levels of ionizing radiation on the development of cancer and
noncancerous disease. This population was exposed to
whole-body ionizing radiation at the time of the bombings in
August of 1945 and has been systematically assessed since
then for the development of disease as part of the LSS
cohort29,36-42. Approximately 25,000 subjects of this cohort
served as ‘‘control subjects,’’ having been exposed to either
no or very minimal (i.e., <0.005 Gy) amounts of radiation
equivalent to annual background radiation doses, which fa-
cilitated comparisons to subjects with exposure to higher doses
(Fig. 2, Table I). As such, the LSS cohort of atomic-bomb
survivors has broadened the understanding of the effects of
ionizing radiation on the development of disease and has
contributed to radiation protection guidelines and prevention
initiatives.
According to an analysis by Preston et al.39, who re-
ported the cancer incidence in atomic-bomb survivors of
Hiroshima and Nagasaki in the LSS cohort, sarcomas as a
group (bone sarcomas included) exhibited an ERR per Gy of
0.48 (90% CI: 0.07 to 1.4), with an EAR of 0.39 per 10,000
per person-year Gy (90% CI: 0.08 to 1.04) at age seventy
years, after exposure at age thirty years, in a linear fashion.
However, according to a recent report by Samartzis et al.29,
bone and soft-tissue sarcomas possess different suscepti-
bilities to ionizing radiation exposure. In fact, Samartzis
et al.29 reported that bone sarcomas present with a linear
dose-response model with a threshold at 0.85 Gy and an
ERR per Gy of 7.5 (95% CI: 1.34 to 1.85 Gy) in excess of
0.85 Gy.
To our knowledge, our study represents one of the
largest and longest prospective evaluations of primary soft-
tissue sarcomas arising in individuals who were exposed to a
single whole-body dose of ionizing radiation. Our analyses
revealed that soft-tissue sarcomas may be associated with
exposure to low to moderately high levels of ionizing radia-
tion, showing a linear dose-response (nonthreshold) model
with an ERR of 1.01 per Gy. This linear dose-response model
is in line with most other cancers attributed to radiation
induction in atomic-bomb survivors of Hiroshima and Na-
gasaki39. Furthermore, negative effect modification of the
ERR by attained age and age at exposure is seen with solid
cancers overall in the LSS population39, but age at exposure
Fig. 3
Nonadjusted survival analysis of patients with soft-tissue sarcomas stratified by the presence of metastases. The overall five-year survival rate was
39%. Five-year survival rates with or without metastases were 17.4% and 53.4%, respectively.
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was only marginally significant in the present analysis. That
age at diagnosis was a significant modifier of the ERR—but
not the EAR—suggests that the excess rate may be constant
with respect to attained age.
The most common histological types of soft-tissue
sarcoma noted in atomic-bomb survivors were leiomyo-
sarcomas and malignant fibrous histiocytomas, which is
also generally similar in other populations52. Although there
are numerically more women with soft-tissue sarcomas in
the study population, the sex distribution of the exposed
population essentially matches the sex distribution of in-
dividuals with soft-tissue sarcomas in the cohort, indicat-
ing no apparent effect of sex on the incidence of sarcoma
induction.
Prognostic outcomes of soft-tissue sarcomas are depen-
dent on numerous factors, such as histology, grade, size, lo-
cation, duration, age of the patient, presence of metastases,
treatment modality, surgical margin status, and age. In our
study, the survival period was less in those individuals who
experienced metastases. Furthermore, the five-year survival
rate of all sarcomas was 39% (17.4% in subjects with metas-
tases), which is much lower than that reported in epidemio-
logical studies in which ionizing radiation exposure was not a
factor. A recent Surveillance, Epidemiology and End Results
(SEER) assessment noted that the five-year survival rate of
all soft-tissue sarcomas was approximately 71%52. However,
studies have shown that radiation-induced sarcomas have
worse prognostic outcomes, which may further explain the
lower survival rate in our study population26-28. As such, our
study further stresses the important clinical impact of radiation-
induced soft-tissue sarcomas and the need to prevent their
occurrence.
With newer modalities, including intensity-modulated
radiation therapy (IMRT), there is some evidence to suggest
that the integral dose over the tissue receiving some dose is
increased and that a larger volume of tissue adjacent to the
target tissue may receive an appreciable dose of radiation53-55.
This effect can be attributed to the greater number of
beams generally utilized to increase conformality in IMRT,
resulting in a greater number of entry and exit points ex-
posed to some dose of radiation therapy. There is also in-
creased leakage from the gantry head and through the
multileaf collimator due to the greater number of monitor
units required to deliver the specified therapeutic dose56. For
example, treatment of deep-seated pelvic tumors with the
use of higher-energy beams to increase dose at depth for
dose escalation57 and superficial tissue sparing58,59 can also
be accompanied by an increased exposure of adjacent nor-
mal tissue due to the production of secondary neutrons60,61.
In this setting, the benefit of an increased ability to sculpt
the dose to the desired target tissues and avoid organs at risk
in the pelvis (such as the bladder and rectum) with IMRT
must be weighed against the potential for increased short-
term and long-term risk to the patient—specifically, the in-
creased risk of induction of secondary malignant tumors,
including sarcomas.
Although our study represents the largest and longest
longitudinal population-based initiative to assess the asso-
ciation between ionizing radiation exposure and soft-tissue
sarcomas, as with any study, there are limitations. Since the
risk factors of soft-tissue sarcomas were not well understood
at the initiation of the LSS, information such as genetic fac-
tors and occupational hazards has not been collected sys-
tematically for all subjects. However, due to the inclusion of
virtually all radiation-exposed persons in the design of the
LSS, such variables are unlikely to be confounded with ra-
diation dose in the cohort, apart from their potential impact
on survival in the interim between exposure and initiation of
cancer follow-up. However, the authors did attempt to ex-
clude certain sarcomas, such as Kaposi sarcoma (none noted
since 1980s), that may have a strong association with viruses
and giant-cell tumors that are benign or have a questionable
malignant nature.
In conclusion, our study attempts to raise awareness
that even moderate levels of ionizing radiation exposure—
from medical imaging, radiation therapy, and environmen-
tal exposure—can lead to the development of soft-tissue
sarcomas. n
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